Risk assessment of accidental falls in patients taking trazodone, quetiapine, or risperidone for insomnia: A single-center, case–control study

Yoshihito Shimizu1 | Masatoshi Taga1 | Yoshimitsu Takahashi1 | Yasuhiko Yamamoto2 | Togen Masauji1

1Department of Pharmacy, Kanazawa Medical University Hospital, Kahoku, Japan
2Medical Safety Division, Kanazawa Medical University Hospital, Kahoku, Japan

Correspondence
Yoshihito Shimizu, Department of Pharmacy, Kanazawa Medical University Hospital, 1-1 Daigaku. Uchinada, Kahoku, Ishikawa 920-0293, Japan. Email: yoshi108@kanazawa-med.ac.jp

Funding information
Kanazawa Medical University Hospital Research Grant-in-Aid for Allied Health Professionals, Grant/Award Number: H2021-6

Abstract
Aim: No consensus has been reached on the association between the risk of falls and antipsychotic and antidepressant drug use. In this study, we evaluated the risk of falls with trazodone, risperidone, and quetiapine, which are recommended for use at Kanazawa Medical University Hospital.

Methods: We reviewed all patients who were admitted to Kanazawa Medical University Hospital between January 1st and December 31st, 2018. We excluded those aged <20 years and those admitted to pediatric, intensive care, and psychiatric wards. Finally, 9273 patients were included. We reviewed the incidence in these patients of accidental falls reported to the medical safety department. We noted whether these patients received trazodone, quetiapine, or risperidone. We also observed whether they were taking a benzodiazepine receptor agonist, which is a known risk factor. We further examined each patient’s age, sex, the department they were visiting, and their diseases. Patients were considered to have taken medication if it was administered within 24 hours before an accidental fall. Multiple logistic regression analysis was used to evaluate the risk of accidental fall.

Results: Multivariate analysis showed that the adjusted odds ratios (OR) for each medication (with 95% confidence intervals) were: trazodone (OR, 0.47 [0.27–0.80]), quetiapine (OR, 1.06 [0.46–2.46]), and risperidone (OR, 0.82 [0.41–1.63]).

Conclusion: The association of risperidone and quetiapine with accidental falls was unclear. Interestingly, however, trazodone may help reduce the risk, which makes it a potential pharmacologic treatment option for insomnia in patients at high risk for accidental falls.

Keywords
accidental fall, insomnia, quetiapine, risperidone, trazodone
1 | INTRODUCTION

Accidental falls are associated with multiple risk factors such as medical history, physical function, environment, and medications. In addition to physical trauma, falls produce fear of falling, which is associated with activity limitation and the loss of independence. It is important to prevent the first accidental fall. For this prevention, it is necessary to understand the risk factors of individual patients.

Patients who are elderly, cognitively impaired, or severely ill are at risk for delirium, and they are commonly prescribed antidepressants and antipsychotics for insomnia. Although antidepressants and antipsychotics have been reported as risk agents for falls, no consensus has been reached on the risk posed by individual agents. For example, risperidone may increase the risk of falls, whereas others may decrease it. Therefore, information on the risk of falls for individual drugs is lacking. With the aim of adding information on the risk of falls, this study evaluated the risk of falls with trazodone, risperidone, and quetiapine use, which are recommended at Kanazawa Medical University Hospital as treatment for insomnia in patients at risk of delirium.

2 | MATERIALS AND METHODS

2.1 | Study design

This case-control study was conducted at Kanazawa Medical University Hospital, an 817-beds regional hospital with 39 departments that provide acute care. We used multiple logistic regression analysis to evaluate risk factors for accidental falls. The study was approved by the hospital’s Ethical Review Committee (No. H297) and conducted in accordance with the Declaration of Helsinki.

Our report complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.

2.2 | Patients

The number of patients to experience accidental falls was expected to be 10 times greater than the number of explanatory variables. Therefore, we examined a one-year period (January 1st to December 31st, 2018). We included patients who were hospitalized during this period, except for those aged <20 years of age or who were admitted to the pediatric, intensive care, or psychiatric wards, which have different nursing systems than the general wards. At Kanazawa Medical University Hospital, accidental falls must be reported to the medical safety department. Patients who experienced accidental falls were defined as those who reported a fall during the study period (Figure 1). Patients who had fallen more than once during the study period were investigated for their first accidental fall.

2.3 | Data collection

Data were retrospectively extracted from medical records. The use of antidepressants and antipsychotics was confirmed [i.e., trazodone, quetiapine and risperidone, which are recommended for use at the hospital]. The drug use history was included even if it was used for the treatment of conditions other than insomnia, such as restlessness, delirium, and behavioral and psychological symptoms of dementia. The following previously-reported risk factors for accidental falls were ascertained: age ≥70 years, male, length of hospital stay ≥14 days, and use of benzodiazepine receptor agonists. Furthermore, the occurrence of the following was recorded:

- Age ≥70 years
- Male
- Length of hospital stay ≥14 days
- Use of benzodiazepine receptor agonists

FIGURE 1 Flowchart of patient selection according to the inclusion criteria for the study

Patients admitted in the target period (n = 10,942)

Participants excluded from the study (n = 1,669)
- Outside the target wards (n = 1,192)
- <20 years old (n = 477)

Participants included in the study (n = 9,273)

Accidental falls (n = 276)

Nonaccidental falls (n = 8,997)
dementia, stroke, depression and diabetes, Parkinson’s disease, and whether or not the patient was admitted any of the following departments: neurosurgery, neurology, cardiology, ophthalmology, orthopedics, and orthopedics. Among benzodiazepine receptor agonists, we noted triazolam because of its reported high risk of falls; brotizolam and zolpidem were noted because of their high prescription volume at our hospital. Patients who fell were considered to have taken medication if it was administered within 24 hours before the accidental fall. Dementia was defined as Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, and vascular dementia. Stroke was defined as lacunar hemorrhage, putaminal hemorrhage, thalamic hemorrhage, subcortical hemorrhage, brainstem hemorrhage, cerebellar hemorrhage, and subcortical hemorrhage.

### 2.4 Statistical analysis

Comparison of categorical data between the two groups was performed using the chi-squared test with Yates’ correction. Multivariate analysis was performed by logistic regression analysis, using the presence or absence of accidental falls as the objective variable. Explanatory variables included the presence or absence of trazodone, quetiapine, and risperidone, as well as significant factors (P<0.1) identified in univariate analysis. Analyses were performed using SPSS version 22 (IBM), using a two-sided significance level of 0.05.

### 3 RESULTS

#### 3.1 Patient backgrounds

Of the 10,942 patients who were admitted during the study period, we excluded 1192 who were not admitted to the targeted wards and 477 who were aged <20 years. Of the remaining 9273 study patients, 276 experienced accidental falls—an incidence rate of 3.0% (Figure 1). The patients’ backgrounds are shown in Table 1.

To determine the variables for multivariate analysis, we performed univariate analysis of previously-reported risk factors for accidental falls, as follows: age ≥70 years, male, length of hospital stay ≥14 days, use of brotizolam, use of triazolam, use of zolpidem, neurosurgery, ophthalmology, dementia, diabetes, and stroke (Table 2).

#### 3.2 Effects of trazodone, quetiapine, and risperidone on accidental falls

Multivariate analysis calculated adjusted odds ratios (OR) with 95% confidence intervals for quetiapine (OR, 1.06 [0.46–2.46]) and risperidone (OR, 0.82 [0.41–1.63]); they were not significant independent factors associated with accidental falls. However, trazodone (OR, 0.47 [0.27–0.80]) was a significant independent factor associated with reducing the risk of accidental falls (Table 3).

Other items detected as independent risk factors significantly associated with accidental falls were triazolam (OR, 2.31 [1.03–5.20]), age ≥70 years (OR, 2.24 [1.69–2.97]), male (OR, 1.39 [1.08–1.80]), length of stay ≥14 days (OR, 3.88 [2.95–5.10]), neurosurgery (OR, 3.96 [2.48–6.33]), and dementia (OR, 3.00 [2.06–4.36]). Ophthalmology (OR, 0.31 [0.13–0.77]) was independently, significantly associated with reducing the risk of accidental falls (Table 3).

### 4 DISCUSSION

We evaluated the effects of the antidepressant trazodone and the antipsychotics quetiapine and risperidone on accidental falls. For quetiapine and risperidone, the effects on accidental falls were unclear; however, trazodone was found to reduce the risk of accidental falls. A possible reason is that trazodone improves insomnia22 and delirium,23 which are both risk factors for falls. Trazodone prolongs slow-wave sleep duration and improves sleep quality through 5-HT2A receptor blockade. Avidan et al.25 reported that sleep medication reduced the risk of falls due to insomnia. Trazodone improves sleep-wake disturbances, one of the factors of delirium, by blocking 5-HT2A receptors and decreases the severity of delirium within a short period of administration. Moreover, Trazodone has a short half-life of 3–6 hours and causes less drowsiness during the day. These results support our findings.

On the contrary, trazodone can increase the risk of falls.27 Its side effects of drowsiness and dizziness are thought to contribute to this risk.27 Furthermore, drowsiness can be induced in a dose-dependent manner.24 It is possible that our hospital’s recommendation to initiate trazodone at a lower dose may have contributed to our different results, compared with those previously-reported. When trazodone is used for the treatment of insomnia, it is recommended to start with a 25 mg dose, which is the practice at Kanazawa Medical University Hospital. The present study confirmed that the patient had taken the medication within 24 h prior to the fall. In the previous report, only the presence or absence of prescription was confirmed, not whether the patient had taken the medication. This point may have affected the results. This study has several limitations. The risk factors we identified (triazolam use, age ≥70 years, male, length of stay ≥14 days, neurosurgery, and dementia) were consistent with previous reports.6,10–14,17 However, our results differed for ophthalmology. Most patients were admitted to the ophthalmology ward for cataract.

| TABLE 1 Characteristics of participants included in the study |
|-----------------|-----------------|-----------------|
| Age, median (IQR) | 68 (56, 77) |
| Male, n (%) | 4981 (54) |
| Hospitalization period, median (IQR) | 7 (2, 17) |

Abbreviation: IQR, interquartile range.
surgery, performed the day after admission. We speculate that early improvement of visual impairment after admission may have reduced the risk of accidental falls. Because this study was conducted at a single institution, there is a possibility of bias regarding the content of medical care and the nursing system. However, the 3% rate of accidental falls is comparable to previously-reported rates of 1.3% and 1.6% in acute care university hospitals. This suggests that our hospital is an appropriate facility to evaluate accidental falls.

In our analyses, we adjusted the medications and diseases that are risk factors for accidental falls. However, the nursing system, motor function, sleep status, and other drugs that may be fall risks, such as suvorexant, the number of concomitant medications, and drug dosages, were not thoroughly investigated and the effects of confounding factors may have intervened. In particular, delirium has been a contributor to accidental falls but it could not be accurately investigated in this retrospective study. However, our results are consistent with the established relationship between insomnia, delirium, and falls, considering the effects of trazodone on sleep and improvement of delirium. We could not investigate the history of falls, which is a risk factor for falls, but we minimized this effect by investigating the first fall during the study period. Future studies are needed to investigate the relationship between insomnia, delirium, and falls, possibly by adding further risk factors as explanatory variables or by conducting randomized controlled trials.

Although we did not determine the effects of quetiapine and risperidone, used as insomnia medications, on accidental falls, we found that trazodone may reduce the risk of falls. Trazodone

| TABLE 2 | Univariate analysis of patient background factors |
|---------|-----------------------------------------------|
| Variable | Accidental fall (n = 276) | Non-accidental fall (n = 8997) | P-value* |
| Age ≥ 70 years | 196 (71.0) | 4038 (44.9) | <0.001 |
| Male | 170 (61.6) | 4811 (53.5) | 0.009 |
| Length of hospital stay ≥14 days | 192 (69.6) | 2724 (30.3) | <0.001 |
| Medication |  |
| Brotizolam | 14 (5.1) | 262 (2.9) | 0.057 |
| Trazodone | 17 (6.2) | 474 (5.3) | 0.607 |
| Triazolam | 7 (2.5) | 78 (0.9) | 0.011 |
| Quetiapine | 7 (2.5) | 101 (1.1) | 0.061 |
| Risperidone | 11 (4.0) | 160 (1.8) | 0.014 |
| Zolpidem | 13 (4.7) | 363 (4.0) | 0.685 |
| Hospital department |  |
| Cardiology | 31 (11.2) | 891 (9.9) | 0.532 |
| Neurology | 15 (5.4) | 213 (2.4) | 0.002 |
| Neurosurgery | 28 (10.1) | 212 (2.4) | <0.001 |
| Ophthalmology | 5 (1.8) | 902 (10.0) | <0.001 |
| Orthopedics | 26 (9.4) | 771 (8.6) | 0.698 |
| Concomitant disease |  |
| Dementia | 46 (16.7) | 327 (3.6) | <0.001 |
| Depression | 7 (2.5) | 114 (1.3) | 0.119 |
| Diabetes | 81 (29.3) | 1834 (20.4) | <0.001 |
| Parkinson’s disease | 3 (1.1) | 41 (0.5) | 0.290 |
| Stroke | 36 (13.0) | 330 (3.7) | <0.001 |

*Chi-square test with Yates correction. Variables are expressed as n (%).

| TABLE 3 | Multiple logistic regression analysis of the risk of accidental fall |
|---------|-------------------------------------------------|
| Variables | Adjusted OR | 95% CI | P-value |
| Trazodone | 0.47 | (0.27, 0.80) | 0.006 |
| Quetiapine | 1.06 | (0.46, 2.46) | 0.890 |
| Risperidone | 0.82 | (0.41, 1.63) | 0.570 |
| Brotizolam | 1.30 | (0.73, 2.30) | 0.369 |
| Triazolam | 2.31 | (1.03, 5.20) | 0.042 |
| Age ≥ 70 years | 2.24 | (1.69, 2.97) | <0.001 |
| Male | 1.39 | (1.08, 1.80) | 0.011 |
| Length of hospital stay ≥14 days | 3.88 | (2.95, 5.10) | <0.001 |
| Neurology | 1.11 | (0.60, 2.07) | 0.734 |
| Neurosurgery | 3.96 | (2.48, 6.33) | <0.001 |
| Ophthalmology | 0.31 | (0.13, 0.77) | 0.011 |
| Dementia | 3.00 | (2.06, 4.36) | <0.001 |
| Diabetes | 1.27 | (0.96, 1.67) | 0.092 |
| Stroke | 1.55 | (0.99, 2.42) | 0.053 |

Abbreviations: OR: odds ratio; CI: confidence interval.
may be an option for the treatment of insomnia in patients at high risk of accidental falls.

**AUTHOR CONTRIBUTIONS**
Yoshihito Shimizu and Masatoshi Taga contributed to the design of the study and drafting of the manuscript. Yoshihito Shimizu and Yasuhiko Yamamoto collected the data. Yoshihito Shimizu and Masatoshi Taga conducted the statistical analysis. Yoshimitsu Takahashi and Togen Masuji participated in the interpretation of data for the study. All authors contributed to the critical revision of the manuscript and approved the final version of the manuscript to be published.

**ACKNOWLEDGMENTS**
This work was supported by the clinical research support office of the Kanazawa Medical University. We thank Fumiyuki Takase for providing assistance in data collection.

**FUNDING INFORMATION**
This study was supported by the Kanazawa Medical University Hospital Research Grant-in-Aid for Allied Health Professionals (H2021-6).

**CONFLICT OF INTEREST**
Authors declare no conflict of interest.

**DATA AVAILABILITY STATEMENT**
The authors cannot make the data publicly available because of restrictions imposed by the ethics committee. Furthermore, the opt-out clearly states that the information will not be disclosed.

**ETHICAL APPROVAL**
The study was approved by the hospital’s Ethical Review Committee (No. H297) and conducted in accordance with the Declaration of Helsinki.

**PATIENT CONSENT STATEMENT**
The requirement to obtain informed consent was waived in this study because the data were retrospectively extracted from electronic medical charts.

**PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES**
We did not reproduce material from other sources.

**REGISTRY AND THE REGISTRATION NO. OF THE STUDY/TRIAL**
Not applicable.

**ANIMAL STUDIES**
n/a

**ORCID**
Yoshihito Shimizu  https://orcid.org/0000-0001-8118-4275

**REFERENCES**
1. Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12(3):425–30.
2. Tromp AM, Puijim SMF, Smit JH, Deeg DJH, Bouter LM, Lips P. Fall-risk screening test: a prospective study on predictors for falls in community-dwelling elderly. J Clin Epidemiol. 2001;54(8):837–44.
3. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40(1):23–9.
4. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70(2):197–245.
5. Murakawa K, Kitamura Y, Watanabe S, Hongo S, Shinomiya K, Sendo T. Clinical risk factors associated with postoperative delirium and evaluation of delirium management and assessment team in lung and esophageal cancer patients. J Pharm Health Care Sci. 2015;28(1):4.
6. Hartikainen S, Lönroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62(10):1172–81.
7. Bozat-Emre S, Doupe M, Kozyrskyj AL, Grymonpre R, Mahmud SM. Atypical antipsychotic drug use and falls among nursing home residents in Winnipeg, Canada. Int J Geriatr Psychiatry. 2015;30(8):842–50.
8. Katz IR, Rupnow M, Kozma C, Schneider L. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry. 2004;12(5):499–508.
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–49.
10. Bhasin S, Gill TM, Reuben DB, Latham NK, Ganz DA, Greene EJ, et al. A randomized trial of a multifactorial strategy to prevent serious fall injuries. N Engl J Med. 2020;383(2):129–40.
11. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25(4):273–8.
12. Najafpour Z, Godarzi Z, Arab M, Yaseri M. Risk factors for falls in hospital in-patients: a prospective nested case control study. Int J Health Policy Manag. 2019;8(5):300–6.
13. Dolatabadi E, Van Ooteghem K, Taati B, Laboni A. Quantitative mobility assessment for fall risk prediction in dementia: a systematic review. Dement Geriatr Cogn Disord. 2018;45(5–6):353–67.
14. Friedman SM, Munoz B, Pocock SJ, Gatzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–49.
15. Liu Y, Yang Y, Liu H, Wu W, Wu X, Wang T. A systematic review and meta-analysis of fall incidence and risk factors in elderly patients after total joint arthroplasty. Med (Baltim). 2020;99(50):e23664.
16. Canning CG, Sherrington C, Lord SR, Close JCT, Heritier S, Heller GZ, et al. Exercise for falls prevention in Parkinson disease: a randomized controlled trial. Neurology. 2015;84(3):304–12.
17. Davis A, Luciano M, Moghekar A, Yasar S. Assessing the predictive value of common gait measure for predicting falls in patients presenting with suspected normal pressure hydrocephalus. BMC Neurol. 2021;21(1):60.
18. Hunderfund ANL, Sweeney CM, Mandrekar JN, Johnson LM, Britton JW. Effect of a multidisciplinary fall risk assessment on falls among neurology inpatients. Mayo Clin Proc. 2011;86(1):19–24.
19. Luiting S, Jansen S, Seppälä LJ, Daams JG, van der Velde N. Effectiveness of cardiovascular evaluations and interventions on fall risk: a scoping review. J Nutr Health Aging. 2019;23(4):330–7.
20. Smith AA, Silva AO, Rodrigues RA, Moreira MA, Nogueira JA, Tura LF. Assessment of risk of falls in elderly living at home. Rev Lat Am Enfermagem. 2017;6(25):e2754.

21. Kobayashi K, Ando K, Inagaki Y, Suzuki Y, Nagao Y, Ishiguro N, et al. Characteristics of falls in orthopedic patients during hospitalization. Nagoya J Med Sci. 2018;80(3):341–9.

22. Stone KL, Ensrud KE, Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med. 2008;9(Suppl. 1):S18–22.

23. Lakatos BE, Capasso V, Mitchell MT, Kilroy SM, Lussier-Cushing M, Sumner L, et al. Falls in the general hospital: association with delirium, advanced age, and specific surgical procedures. Psychosomatics. 2009;50(3):218–26.

24. Maeda I, Inoue S, Uemura K, Tanimukai H, Hatano Y, Yokomichi N, et al. Low-dose trazodone for delirium in patients who received specialist palliative care: a multicenter prospective study. J Palliat Med. 2021;24(6):914–8.

25. Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53(6):955–62.

26. Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14(7-8):24–34.

27. Jung YS, Suh D, Choi HS, Park HD, Jung SY, Suh DC. Risk of fall-related injuries associated with antidepressant use in elderly patients: a Nationwide matched cohort study. Int J Environ Res Public Health. 2022;19(4):2298.

28. Nakai A, Akedo M, Kawabata I. Incidence and risk factors for inpatient falls in an academic acute-care hospital. J Nippon Med Sch. 2006;73(5):265–70.

29. Tanaka M, Suemaru K, Ikegawa Y, Tabuchi N, Araki H. Relationship between the risk of falling and drugs in an academic hospital. Yakugaku Zasshi. 2008;128(9):1355–61.

How to cite this article: Shimizu Y, Taga M, Takahashi Y, Yamamoto Y, Masauji T. Risk assessment of accidental falls in patients taking trazodone, quetiapine, or risperidone for insomnia: A single-center, case-control study. Neuropsychopharmacol Rep. 2022;42:532–537. https://doi.org/10.1002/npr2.12297